Overview

A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.

Status:
Completed

Trial end date:
2021-09-04

Target enrollment:

Participant gender:

Summary

This is a phase 1, single-centre, single-group, nonrandomised, noncomparative, open-label, single-dose study to evaluate the safety, biodistribution, internal radiation dosimetry, and effective dose of DaTSCAN™ ioflupane (123I) injection in Chinese Healthy Volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

GE Healthcare

Collaborator:

PPD